The association between hyperandrogenemia and the metabolic syndrome in morbidly obese women
Open Access
- 21 May 2015
- journal article
- research article
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 7 (1) , 1-10
Abstract
Female abdominal obesity is associated with hyperandrogenemia (HA), but few studies have addressed the possible association between HA and metabolic syndrome (MetS) among obese women. Some studies indicate that insulin resistance may cause HA through different mechanisms. On the other hand, a bidirectional relationship between HA and insulin resistance has been suggested. Thus, we aimed to investigate if morbidly obese women with HA had higher odds of MetS and its components than those without HA (controls), independent of polycystic ovarian syndrome (PCOS) status. This cross-sectional study comprised 1900 consecutive treatment seeking morbidly obese women 0.6 defined HA. Women with previously diagnosed PCOS and those with oligo- / anovulation combined with clinical or biochemical hyperandrogenism were defined as having PCOS. Multiadjusted associations between HA and MetS were assessed by logistic regression analysis. Out of 1900 morbidly obese women, 1089 (57 %), 846 (45 %) and 312 (16 %) had MetS, HA and PCOS, respectively. Compared with controls (without HA), women with HA were younger (34 [1] years vs. 39 [2], p < 0.001) had a higher prevalence of MetS (62 % vs. 53 %, p < 0.001), type 2 diabetes (18 % vs. 15 %, p = 0.045), low HDL-cholesterol (65 % vs. 48 %, p < 0.001) and hypertriglyceridemia (48 % vs. 41 %, p = 0.004), but a lower prevalence of raised blood pressure (53 % vs. 59 %, p = 0.014). Multivariable analyses showed that HA was associated with increased odds of MetS (OR 1.61 [95 % CI 1.27, 2.02]), dysglycemia (1.65 [1.28, 2.11]), low HDL-cholesterol (1.58 [1.27, 1.97]), and hypertriglyceridemia (1.43 [1.15, 1.79]). After stratification for the presence of PCOS, the results remained largely unchanged in women without PCOS; MetS (1.52 [1.18, 1.96), dysglycemia (1.71 [1.30, 2.25]), low HDL-cholesterol (1.55 [1.22, 1.98]) and hypertriglyceridemia (1.36 [1.06, 1.74]). Morbidly obese women with HA had an approximately 1.5-fold increased odds of having MetS even in the absence of PCOS. Randomized controlled clinical trials, including therapeutic strategies to lower free testosterone levels, are however necessary to explore any cause-and-effect relationship.Keywords
This publication has 42 references indexed in Scilit:
- Low sex hormone-binding globulin is associated with hypertension: a cross-sectional study in a Swedish populationBMC Cardiovascular Disorders, 2013
- Relative Contributions of Oligomenorrhea and Hyperandrogenemia to the Risk of Metabolic Syndrome in Midlife WomenThe Journal of Clinical Endocrinology & Metabolism, 2012
- Testosterone increases the muscle protein synthesis rate but does not affect very-low-density lipoprotein metabolism in obese premenopausal womenAmerican Journal of Physiology-Endocrinology and Metabolism, 2012
- Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespanBMC Medicine, 2010
- Human Ovarian Reserve from Conception to the MenopausePLOS ONE, 2010
- The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteriaHuman Reproduction, 2009
- Harmonizing the Metabolic SyndromeCirculation, 2009
- Impact of Obesity on the Risk for Polycystic Ovary SyndromeThe Journal of Clinical Endocrinology & Metabolism, 2008
- In vitro bioassays for androgens and their diagnostic applicationsHuman Reproduction Update, 2007
- World Medical Association Declaration of HelsinkiJAMA, 2000